ATLAS mPBPK: A MATLAB‐Based Tool for Modeling and Simulation of Minimal Physiologically‐Based Pharmacokinetic Models

Minimal physiologically‐based pharmacokinetic (mPBPK) models are frequently used to model plasma pharmacokinetic (PK) data and utilize and yield physiologically relevant parameters. Compared with classical compartment and whole‐body physiologically‐based pharmacokinetic modeling approaches, mPBPK models maintain a structure of intermediate physiological complexity that can be adequately informed by plasma PK data. In this tutorial, we present a MATLAB‐based tool for the modeling and simulation of mPBPK models (ATLAS mPBPK) of small and large molecules. This tool enables the users to perform the following: (i) PK data visualization, (ii) simulation, (iii) parameter optimization, and (iv) local sensitivity analysis of mPBPK models in a simple and efficient manner. In addition to the theoretical background and implementation of the different tool functionalities, this tutorial includes simulation and sensitivity analysis showcases of small and large molecules with and without target‐mediated drug disposition.

[1]  F. Magrini,et al.  Extended Report , 2011 .

[2]  Sebastian Schneckener,et al.  Development and validation of a physiology-based model for the prediction of pharmacokinetics/toxicokinetics in rabbits , 2018, PloS one.

[3]  K Rowland-Yeo,et al.  Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development , 2013, CPT: pharmacometrics & systems pharmacology.

[4]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[5]  William J. Jusko,et al.  Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model , 2015, Pharmaceutical Research.

[6]  D. DuBois,et al.  Interrelationships between Infliximab and Recombinant Tumor Necrosis Factor-α in Plasma Using Minimal Physiologically Based Pharmacokinetic Models , 2017, Drug Metabolism and Disposition.

[7]  Malcolm Rowland,et al.  Lumping of Whole-Body Physiologically Based Pharmacokinetic Models , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[8]  A. Kamath,et al.  Minimal physiologically-based pharmacokinetic modeling of DSTA4637A, A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus, in a mouse model , 2018, mAbs.

[9]  H. Wiig,et al.  Interstitial exclusion of positively and negatively charged IgG in rat skin and muscle. , 2001, American journal of physiology. Heart and circulatory physiology.

[10]  J E Simmons,et al.  Applications of sensitivity analysis to a physiologically based pharmacokinetic model for carbon tetrachloride in rats. , 1994, Toxicology and applied pharmacology.

[11]  M Rowland,et al.  Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions , 2012, Clinical pharmacology and therapeutics.

[12]  E. Laemmel,et al.  Towards a better understanding of lymph circulation , 2008 .

[13]  Modeling Sex Differences in Anti-inflammatory Effects of Dexamethasone in Arthritic Rats , 2018, Pharmaceutical Research.

[14]  W. Jusko,et al.  Minimal physiologically-based pharmacokinetic (mPBPK) model for a monoclonal antibody against interleukin-6 in mice with collagen-induced arthritis , 2016, Journal of Pharmacokinetics and Pharmacodynamics.

[15]  William J. Jusko,et al.  Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model , 2014, Journal of Pharmacokinetics and Pharmacodynamics.

[16]  William J. Jusko,et al.  Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies , 2013, Journal of Pharmacokinetics and Pharmacodynamics.

[17]  D. DuBois,et al.  Characterization and Interspecies Scaling of rhTNF-α Pharmacokinetics with Minimal Physiologically Based Pharmacokinetic Models , 2017, Drug Metabolism and Disposition.

[18]  D. DuBois,et al.  Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats , 2007, Biopharmaceutics & drug disposition.

[19]  M. Roberts,et al.  The effect of posture on the pharmacokinetics of intravenous benzylpenicillin , 2004, European Journal of Clinical Pharmacology.

[20]  Ioannis P. Androulakis,et al.  A framework for 2-stage global sensitivity analysis of GastroPlus™ compartmental models , 2018, Journal of Pharmacokinetics and Pharmacodynamics.

[21]  Y. Sasaki,et al.  Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer , 1999, British Journal of Cancer.

[22]  M. Roberts,et al.  The effects of posture on the pharmacokinetics of intramuscular benzylpenicillin , 2004, European Journal of Clinical Pharmacology.

[23]  D. DuBois,et al.  Modeling Sex Differences in Pharmacokinetics, Pharmacodynamics, and Disease Progression Effects of Naproxen in Rats with Collagen-Induced Arthritis , 2017, Drug Metabolism and Disposition.

[24]  Leon Aarons,et al.  Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data , 2015, British journal of clinical pharmacology.

[25]  M. De Carlo,et al.  Interstitial exclusion of IgG in rat tissues estimated by continuous infusion. , 1994, The American journal of physiology.

[26]  William J. Jusko,et al.  Applications of minimal physiologically-based pharmacokinetic models , 2012, Journal of Pharmacokinetics and Pharmacodynamics.

[27]  William J. Jusko,et al.  Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies , 2014, Journal of Pharmacokinetics and Pharmacodynamics.

[28]  Leonid Gibiansky,et al.  Approximations of the target-mediated drug disposition model and identifiability of model parameters , 2008, Journal of Pharmacokinetics and Pharmacodynamics.

[29]  D. DuBois,et al.  Modeling Combined Immunosuppressive and Anti-inflammatory Effects of Dexamethasone and Naproxen in Rats Predicts the Steroid-Sparing Potential of Naproxen , 2017, Drug Metabolism and Disposition.

[30]  William J Jusko,et al.  Moving from basic toward systems pharmacodynamic models. , 2013, Journal of pharmaceutical sciences.

[31]  L Zhang,et al.  Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.

[32]  Hemant Sarin,et al.  Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability , 2010, Journal of angiogenesis research.

[33]  Kevin McNally,et al.  A Workflow for Global Sensitivity Analysis of PBPK Models , 2011, Front. Pharmacol..